¥Ñ©ó¬ü°ê¡B¥[®³¤j¡B¤é¥»µ¥°ê¡A³£¤w³W©w§tergotamine¤Îdihydroergotamine¦¨¤ÀªºÃÄ«~¶·±N¬ÛÃö·ÀI¥Z¸ü©ó¥é³æ¡u¸T§Ò¯g¡v³B¡A¦A¥[¤W¤åÄm¸ê®Æ¡BÃĪ«¥æ¤¬§@¥Î·ÀIµ{«×¤§¬ÛÃöÃÒ¾Ú¡A¦]¦¹¹Ãĸpn¨D5ºØergot-alkaloidÃþ¦¨¤ÀÃÄ«~¡A¶·¨Ì¥H¤U«ØijÅܧ󤤤å¥é³æ¡G
¡´§tergotamine¤Îdihydroergotamine¦¨¤ÀÃÄ«~¡G
©ó¡u¥[®Øĵ»y¡v¡B¡uĵ»y¤Îª`·N¨Æ¶µ¡v¤Î¡u¥æ¤¬§@¥Î¡vµ¥³B¥Z¸ü¦X¨Ö¨Ï¥Î±j®ÄCYP3A4 §í¨î¾¯¤§¬ÛÃö·ÀI¡C
¡´§tergometrine¡]ergonovine¡^¤Îmethylergometrine¡]methylergonovine¡^¦¨¤ÀÃÄ«~¡G
©ó¡uĵ»y¤Îª`·N¨Æ¶µ¡v¤Î¡u¥æ¤¬§@¥Î¡v³B¥Z¸ü¦X¨Ö¨Ï¥Î±j®ÄCYP3A4§í¨î¾¯¤§¬ÛÃö·ÀI¡C
¡´§tbromocriptine¦¨¤ÀÃÄ«~¡G
©ó¡u¥æ¤¬§@¥Î¡v³B¥Z¸ü¦X¨Ö¨Ï¥Î±j®ÄCYP3A4§í¨î¾¯¤§¬ÛÃö·ÀI¡C
¤¤¤å¥é³æÅܧ󶷦b113¦~12¤ë2¤é«e§¹¦¨¡A¹O´Á¥¼§¹¦¨ªÌ±N¼o¤î³\¥iÃÒ¡C¹Ãĸp¤]´£¿ô¡AÂå®vÀ³ÁקK³B¤è¨Ö¥Î³o¨ÇÃÄ«~©ó¯f¤H¨¤W¡A¥t¥~¥Á²³Y¦b¨Ï¥Î³o¨ÇÃÄ«~´Á¶¡¥X²{¥ô¦ó¤£¾A¯gª¬¡AÀ³¥ß§Y§iª¾ÂåÀø¤Hû©Î´M¨DÂåÀø¨ó§U¡C
YÃhºÃ¦³¨Ï¥Î¡]ªA¥Î¡^ÃÄ«~¦Ó¾ÉP¤£¨}¤ÏÀ³µo¥Í®É¡A¥i¥ß§Y³q³ø½ÃºÖ³¡©Ò«Ø¸m¤§¡u¥þ°êÃĪ«¤£¨}¤ÏÀ³³q³ø¤¤¤ß¡v¡AÃĪ«¤£¨}¤ÏÀ³³q³ø±M½u 02-2396-0100¡Aºô¯¸¡G
https://adr.fda.gov.tw¡C
¥»¤å¸g °·±dÂåÀøºô ±ÂÅv¥Zµn¡Aì¤åµoªí
©ó¦¹
¡i°·±dÂåÀøºô¡þ°OªÌ§d»ö¤å³ø¾É¡j2024/04/10